Troy Swan, Winc | Staples + OfficeMax + Corporate Express

Troy Swan, Winc | Staples + OfficeMax + Corporate Express
In-House Leaders 2020

general counsel and company secretary

Troy Swan is the general counsel, company secretary, and director of the $1.3 billion office-products company Winc, which was formed following the acquisition and merger of Staples, Corporate Express, and OfficeMax.

Swan played a pivotal role in the sale of Staples and Corporate Express and the acquisitions of OfficeMax Australia and OfficeMax New Zealand. Following the successful execution of the multi-asset acquisition plan, Swan and the legal team had been tasked with the transformation of the Winc brand, increasing the legal IQ of the combined organisation, as well as managing all the legal aspects associated with a billion-dollar merger. The team is also legal tech early adopters and supporters, being pilot partners for several emerging innovators, and recently deployed their first legal bot in partnership with Automio.     

Most Read

Last year, Swan has been a finalist for Australian General Counsel of the Year and has been named on the GC Powerlist Australia. 

Free newsletter

Subscribe to our FREE newsletter service and we’ll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.

Please enter your email address below and click on Sign Up for daily newsletters from Australasian Lawyer.

Recent articles & video

Australian law firms to set new working parameters

Final week to find the legal profession’s emerging leaders

Partner at major firm defends destroying notes after internal bullying investigation

Major legal consultancy in the UK appoints new managing director

Lawyers need to acknowledge their value, EY Law partner says

Boutique firm’s practice director among Global Banking Regulation Review’s 45 under 45

Most Read Articles

HWL in shock IPO decision

Risk advisory head tapped as NRF's next Australia chair

MinterEllison acts on $446m sale of cancer treatment facility

Troubled insurer rocked by more allegations